Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alexion

Alexion
1992 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
ALXN STOCK SYMBOL
16 INVESTMENTS
$108.53 SHARE PRICE (As of Wednesday Closing)
Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 121 Seaport Boulevard
  • Boston, MA 02210
  • United States

+1 (475) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alexion’s full profile, request a free trial.

Alexion Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$92.56 - $141.86 $24B $110.65 $6.57 2.24M 221M

Alexion Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 22,601,580 23,391,288 28,451,559 29,600,640
Revenue 4,735,600 4,131,200 3,551,100 3,084,100
EBITDA 2,009,100 745,700 1,142,900 1,069,500
Net Income 1,470,300 77,600 443,300 399,400
Total Assets 14,815,000 13,931,900 13,583,300 13,253,300
Total Debt 2,700,100 3,206,500 3,231,000 3,288,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alexion Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alexion‘s full profile, request access.

Request full access to PitchBook

Alexion Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioMarin Pharmaceutical Formerly VC-backed Novato, CA 0000 000.00 000000000 000.00
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Alexion Investments & Acquisitions (16)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 16-Oct-2019 000000000000000000 00000 Pharmaceuticals 000000 0000000 00.0
00000 000000000000 09-Sep-2019 0000 0000 Drug Discovery 0000 000000 00
000000 00000000000 30-Jan-2019 000000000 0000 Biotechnology
0000000000 02-Nov-2018 000000000000000000 00.00 Biotechnology 000000 0000000 00.0
Dicerna (RNAi therapies) 24-Oct-2018 Corporate Asset Purchase Biotechnology 000000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Alexion Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 05-Jan-2015 00000 00000 00 00000 Completed
  • 9 buyers
0000000 0000000000 22-Jan-2014 00000 00000 00 00000 Completed
  • 4 buyers
PhaseRx 02-Oct-2013 Convertible Debt 00.00 Completed
To view this company’s complete exits history, request access »

Alexion Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Alexion‘s full profile, request access.

Request full access to PitchBook

Alexion Executive Team (38)

Name Title Board
Seat
Contact
Info
Ludwig Hantson Ph.D Chief Executive Officer & Board Member
Aradhana Sarin Chief Financial Officer & Executive Vice President
Indrani Franchini JD Executive Vice President & Chief Compliance Officer
Tanisha Carino Ph.D Chief Corporate Affairs Officer & Executive Vice President
Anne-Marie Law Executive Vice President & Executive

30 Former Executives

You’re viewing 5 of 38 executives. Get the full list »

Alexion Board Members (10)

Name Representing Role Since Contact
Info
Andreas Rummelt Ph.D Self Board Member 000 0000
David Brennan Alexion Chairman & Board Member 000 0000
Francois Nader Ph.D Self Board Member 000 0000
Judith Reinsdorf Alexion Board Member 000 0000
Ludwig Hantson Ph.D Alexion Chief Executive Officer & Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »